Zucker Featured in the Daily Journal as a Top Biotech Lawyer in California

August 11, 2011 O’Melveny & Myers LLP partner Sam Zucker was profiled in the August 11, 2011, edition of the Daily Journal as part of the publication’s report on the “Top 25 Biotech Lawyers in California.” Zucker, who is a member of the Firm’s Mergers and Acquisitions practice, notes in the profile that there have been some “significant changes” in the area of biotech and that the “traditional model of biotech is largely broken” considering the newfound difficulty associated with gaining approval for a device or drug through the United States Food and Drug Administration. With respect to emerging biotech companies Zucker said, “we're seeing the rise of companies finding different approaches to reducing risks to investors," which includes identifying countries with needs for particular treatments and an increase in health care efficiency companies that provide investors information and transparency while managing costs. According to Zucker, large pharmaceutical companies are looking to invigorate their product pipelines and are eager to associate with companies in their nascent stage.

The article also highlights several recent biotech transactions Zucker has handled, including a US$220 million public offering for Nektar Therapeutics; the closing of a US$60 million financing for Castlight Health and his advisement of the company in additional partnerships; the sale of BiPar Sciences Inc. to Sanofi-aventis, which is valued at up to US$500 million; his representation of Alta Partners in its US$111 million sale of Taligen Therapeutics Inc. to Alexion Pharmaceuticals Inc.; and his representation of Celsion Corp. on registered direct and private placement financings totaling US$33 million.